Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04459715
Recruitment Status : Recruiting
First Posted : July 7, 2020
Last Update Posted : November 23, 2021
Sponsor:
Collaborator:
GORTEC (Head and Neck Oncology and Radiotherapy Group)
Information provided by (Responsible Party):
Debiopharm International SA

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 1, 2024
Estimated Study Completion Date : April 30, 2027